Welcome to our dedicated page for Koninklijke Phil SEC filings (Ticker: PHG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CPAP recall costs, global supply-chain shifts, and segment revenue swings make Philips disclosures anything but straightforward. If combing through a 200-page note to find Connected Care recall provisions or tracking when executives dispose of shares feels overwhelming, you’re not alone.
Stock Titan turns that complexity into clarity. Our AI surfaces what matters in every form—whether you need the Philips quarterly earnings report 10-Q filing for margin trendlines or a Philips insider trading Form 4 transactions alert before market open. Click once and you’ll see Philips SEC filings explained simply: concise summaries, plain-language definitions, and cross-links that walk you through goodwill impairments, imaging backlog commentary, and R&D capitalization.
Use cases investors rely on daily:
- Instant push when a Philips 8-K material events explained posts—critical for recall updates.
- Side-by-side Philips earnings report filing analysis to compare Diagnosis & Treatment growth QoQ.
- Monitor Philips Form 4 insider transactions real-time and spot buying ahead of new MRI launches.
The platform covers every disclosure—Philips annual report 10-K simplified, Philips proxy statement executive compensation, even niche Philips executive stock transactions Form 4—with AI-powered highlights, real-time EDGAR updates, and expert commentary. Stop sifting through footnotes; start understanding Philips SEC documents with AI and make informed decisions faster.
Koninklijke Philips N.V. reported Q3 2025 results showing continued momentum: comparable order intake grew 8% and group sales were EUR 4.3 billion, up 3.3% on a comparable basis. Income from operations was EUR 330 million. The adjusted EBITA margin rose 50 bps to 12.3% as higher sales, mix and productivity more than offset tariff headwinds.
Operating cash flow was EUR 327 million with free cash flow of EUR 172 million. Segment trends were mixed: Diagnosis & Treatment comparable sales grew 1.3% with margin at 11.8% (down 80 bps), Connected Care grew 5.1% with margin up 410 bps to 11.4%, and Personal Health grew 10.9% with margin at 17.1%.
Philips reiterated its full‑year 2025 outlook: comparable sales growth of 1%–3%, adjusted EBITA margin of 11.3%–11.8% now expected toward the upper end, and free cash flow of EUR 0.2–0.4 billion, which includes the EUR 1,025 million settlements paid in Q1 2025. The outlook excludes ongoing Philips Respironics‑related proceedings.
FAQ
What is the current stock price of Koninklijke Phil (PHG)?
What is the market cap of Koninklijke Phil (PHG)?
